More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$14.40B
EPS
-2.96
P/E ratio
--
Price to sales
15.95
Dividend yield
--
Beta
0.688044
Previous close
$244.88
Today's open
$242.60
Day's range
$239.65 - $247.12
52 week range
$87.32 - $255.19
show more
CEO
Thomas W. Burns
Employees
1094
Headquarters
Aliso Viejo, CA
Exchange
New York Stock Exchange
Shares outstanding
59196870
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
What Drove Glaukos Stock's 48% Rally Since the End of September?
Glaukos shares have surged 48.2% since September-end, fueled by strong Q3 results, raised sales guidance, Epioxa and iDose TR growth, and positive clinical data.
Zacks Investment Research • 9 hours ago

NVIDIA Governance Woes: 3 Areas to Buy From Amid AI Market Slump
NVIDIA's controversy and AI market correction prompt investors to explore healthcare, consumer staples and selective semiconductor opportunities.
Zacks Investment Research • Nov 10, 2026

Glaukos Announces Participation in Upcoming Investor Conferences
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences:Stifel Healthcare Conference on Tuesday, November 10, 2026, at 8:40 a.m. ET in New York City, NYJefferies Global Healthcare Conference on Wednesday, November.
Business Wire • Nov 3, 2026

Okta Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
NEW YORK, Oct. 30, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600 effective prior to the opening of trading on Wednesday, November 4: S&P MidCap 400 constituent Okta Inc. (NASD: OKTA) will replace Kenvue Inc. (NYSE: KVUE) in the S&P 500, S&P SmallCap 600 constituent Glaukos Corp. (NYSE: GKOS) will replace Okta in the S&P MidCap 400, and McGrath RentCorp (NASD: MGRC) will replace Glaukos in the S&P SmallCap 600. S&P 500 constituent Kimberly-Clark (NASD: KMB) is acquiring Kenvue in a deal expected to be completed soon, pending final closing conditions.
PRNewsWire • Oct 30, 2026

Glaukos Analysts Boost Their Forecasts Following Better-Than-Expected Q3 Earnings
Glaukos Corp (NYSE:GKOS) on Wednesday reported better-than-expected third-quarter financial results and raised its FY26 sales guidance above estimates.
Benzinga • Oct 29, 2026

Glaukos Sets $1 Billion 2027 Sales Goal: Rapid Earnings Reaction
Glaukos raised its 2026 sales forecast to $775 million to $785 million and set a preliminary 2027 target of $1 billion, after third-quarter sales jumped 58% to $211.0 million. Profit is thinner than the adjusted figures suggest.
The Motley Fool • Oct 29, 2026

Why Glaukos Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
Shares of Glaukos Corp (NYSE:GKOS) rose sharply in pre-market trading after the company reported better-than-expected third-quarter financial results and raised its FY26 sales guidance above estimates.
Benzinga • Oct 29, 2026

Glaukos Q3 Earnings Call Highlights
Glaukos NYSE: GKOS reported record third-quarter consolidated net sales of $211 million, up 58% from the year-earlier period, led by growth in its Epioxa corneal health therapy and iDose TR glaucoma treatment. The company raised its full-year 2026 revenue outlook and introduced a preliminary target of $1 billion in revenue for 2027.
MarketBeat • Oct 28, 2026

Glaukos Corporation (GKOS) Q3 2026 Earnings Call Transcript
Glaukos Corporation (GKOS) Q3 2026 Earnings Call Transcript
Seeking Alpha • Oct 29, 2026

Glaukos Announces Third Quarter 2026 Financial Results
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the third quarter ended September 30, 2026. Key highlights include: Record net sales of $211.0 million in Q3 2026 increased 58% year-over-year on a reported and constant currency basis. U.S. Glaucoma record net sales of $118.6 mil.
Business Wire • Oct 28, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Glaukos Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.